150 related articles for article (PubMed ID: 16944009)
1. The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study.
Bolukbas C; Bolukbas FF; Kendir T; Akbayir N; Ince AT; Abut E; Horoz M; Dalay AR; Sokmen MH; Ovunc O
Dig Dis Sci; 2006 Jul; 51(7):1196-202. PubMed ID: 16944009
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
[TBL] [Abstract][Full Text] [Related]
3. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation.
Andreone P; Biselli M; Gramenzi A; Cursaro C; Morelli MC; Sama C; Lorenzini S; Spinucci G; Porzio F; Felline F; Di Giammarino L; Bernardi M
Transplantation; 2002 Oct; 74(8):1119-24. PubMed ID: 12438957
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
Yao FY; Terrault NA; Freise C; Maslow L; Bass NM
Hepatology; 2001 Aug; 34(2):411-6. PubMed ID: 11481627
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine treatment of decompensated hepatitis B virus-related cirrhosis.
Zhang FK
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):10-5. PubMed ID: 16481275
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
8. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
9. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM
J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
11. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
Hann HW; Fontana RJ; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Gardner SD; Brown N; Griffiths D;
Liver Transpl; 2003 Jan; 9(1):49-56. PubMed ID: 12514773
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.
Hiraoka A; Michitaka K; Kumagi T; Kurose K; Uehara T; Hirooka M; Yamashita Y; Kubo Y; Miyaoka H; Iuchi H; Okada S; Ohmoto M; Yamamoto K; Horiike N; Onji M
Oncol Rep; 2005 Jun; 13(6):1159-63. PubMed ID: 15870937
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
Hyun JJ; Seo YS; Yoon E; Kim TH; Kim DJ; Kang HS; Jung ES; Kim JH; An H; Kim JH; Yim HJ; Yeon JE; Lee HS; Byun KS; Um SH; Kim CD; Ryu HS
Liver Int; 2012 Apr; 32(4):656-64. PubMed ID: 22099071
[TBL] [Abstract][Full Text] [Related]
14. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Matthews GV; Cooper DA; Dore GJ
Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
[TBL] [Abstract][Full Text] [Related]
15. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
[TBL] [Abstract][Full Text] [Related]
16. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
17. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
[TBL] [Abstract][Full Text] [Related]
18. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
Bae SH; Yoon SK; Choi JY; Jang JW; Cho SH; Yang JM; Han NI; Ahn BM; Chung KW; Sun HS
J Gastroenterol Hepatol; 2005 Oct; 20(10):1527-32. PubMed ID: 16174069
[TBL] [Abstract][Full Text] [Related]
19. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
20. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
